Vostok New Ventures återköper depåbevis


Stockholm, Aug. 19, 2019 (GLOBE NEWSWIRE) --

Vostok New Ventures Ltd ("Vostok New Ventures" eller "Bolaget") har mellan den 14 augusti och den 16 augusti 2019 återköpt 32 400 ordinarie depåbevis (SDB) i Bolaget till ett genomsnittligt pris om 60,90 SEK. Detta motsvarar 0,04% av det totala antalet ordinarie depåbevis i Vostok New Ventures. Bolaget innehar totalt 7 640 503 återköpta ordinarie depåbevis. Det totala antalet utestående ordinarie depåbevis i Vostok New Ventures, exklusive återköpta depåbevis, uppgår till 78 194 806.

För ytterligare information, vänligen kontakta:
Björn von Sivers, Investor Relations: +46 (0)8 545 015 50

Vostok New Ventures Ltd är ett investmentbolag vars affärsidé är att genom erfarenhet, kunskap och ett omfattande nätverk identifiera och investera i tillgångar med stor värdeökningspotential. Bolaget har ett särskilt fokus på digitala marknadsplatser och företag med starka nätverkseffekter. Vostok New Ventures depåbevis (SDB) är noterade på Nasdaq Stockholm, Mid Cap-segmentet, under kortnamnet VNV SDB. För mer information om Vostok New Ventures, besök .



One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Orange Industry 4.0 Campus welcomes co-innovation of Port of Antwerp, Borealis, Covestro and other industrial partners, maximizing 5G potential in the port of Antwerp22.1.2020 13:54:00 CETPress release

Press Release Brussels, 22 January 2020 Orange Industry 4.0 Campus welcomes co-innovation of Port of Antwerp, Borealis, Covestro and other industrial partners, maximizing 5G potential in the port of Antwerp Orange Belgium is now welcoming its first wave of industrial partners to the Orange Industry 4.0 Campus for business. The Port of Antwerp, the chemical company Borealis and high-tech polymer manufacturer Covestro started to co-innovate to developing real-life applications, maximizing the full potential of 5G at Orange Belgium’s testing hub. Deloitte Belgium will advise the community on shaping and realizing the business potential of this 5G innovation hub. With Orange’s 5G testing network being deployed on the campus, industrial partners will benefit from dedicated connectivity and a guaranteed service quality appropriate for their specific use cases. Orange Belgium launched this 5G testing network in Antwerp in late 2019 and it is the country’s first 5G stand-alone architecture net

Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion Corporation22.1.2020 11:45:00 CETPress release

ORION CORPORATION STOCK EXCHANGE RELEASE 22 JANUARY 2020 at 12.45 EET Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion Corporation The Nomination Committee of Orion Corporation has on 22 January 2020 given to the company’s Board of Directors its recommendation for the proposal to the Annual General Meeting of 2020 concerning the composition of the Board of Directors to be elected by the meeting. The Committee recommends that the following proposal be presented to the AGM of 2020: The number of Board members would be seven. Of the present members of the Board, Pia Kalsta, Ari Lehtoranta, Timo Maasilta, Hilpi Rautelin, Eija Ronkainen and Mikael Silvennoinen would be re-elected for the next term of office and Kari Jussi Aho MSc (Econ. and Bus. Adm.) would be elected as a new member. Mikael Silvennoinen would be elected as Chairman of the Board. Silvennoinen has been a member of the Orion Board of Directors since 2014 and c

Orion publishes Financial Statement Release for 2019 on 5 February 202022.1.2020 08:00:00 CETPress release

ORION CORPORATION PRESS RELEASE 22 JANUARY 2019 at 09.00 EET Orion will publish its Financial Statement Release for 2019 on Wednesday, 5 February 2020 approximately at 12.00 noon EET. The release and related presentation material will be available on the company’s website at after publishing. News conference A news conference and a conference call for analysts, investors and media will be held on Wednesday, 5 January 2020 at 13.30 EET at Orion's head office, address Orionintie 1A, Espoo. Participants are requested to present a photo ID at the head office reception. A link to the live webcast will be available on Orion's website at A recording of the event will be available on the website later the same day. To participate the conference call, please dial: Finland: +358 9 817 103 10 Sweden: +46 8 566 426 51 UK: +44 33 3300 0804 USA: +1 855 857 0686 PIN: 45651029# Silent period The silent period preceding the publication is ongoing and

Prosafe SE: Q4 2019 results and webcast on 6 February 202022.1.2020 07:30:00 CETPress release

Prosafe SE will release its fourth quarter 2019 results on 6 February 2020 at approx. 07:00 a.m. CET. Jesper Kragh Andresen, CEO and Stig H. Christiansen, Deputy CEO & CFO will the same day at 10:00 a.m. CET present the results at Felix Konferansesenter, Bryggetorget 3, Oslo. The presentation can be followed live via web streaming at It will be possible to ask questions during the presentation by using the Q&A tool embedded in the webcast. The webcast will be available for replay at Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to Stavanger, 22 January 2020 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig Harry Christiansen, Deputy CEO and CFO Phone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosur

Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer22.1.2020 07:15:00 CETPress release

Extension of existing agreement with Roche for supply of PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) Basel, Switzerland, January 22, 2020 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it extended its clinical supply agreement (CSA) with Roche (SIX: RO, ROG) to explore a combination of Basilea’s panFGFR kinase inhibitor derazantinib and Roche’s atezolizumab (Tecentriq®)1 in patients with gastric (stomach) cancer. The initial CSA covered urothelial (bladder) cancer and was concluded in January 2019. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study (FIDES-03) in advanced gastric cancer patients with FGFR genetic aberrations in the third quarter of 2020. The study will assess the efficacy and safety of derazantinib as mono- and combination therapy in the second-line setting. Basilea will be the sponsor of the study and Roche will provide clinical supply of atezolizumab, a PD-L1 checkpoint inhibitor. Dr. Marc Engelhardt, Chief Medical Officer